| Recruiting | Spartina® (Tirzepatide) Effectiveness and Safety Evaluation Obesity & Overweight | — | 2025-11-11 |
| Completed | Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients Mucopolysaccharidosis Type 1 | Phase 3 | 2022-09-10 |
| Completed | Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years COVID-19 | Phase 3 | 2022-02-23 |
| Completed | Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two COVID-19 | N/A | 2022-02-04 |
| Completed | Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine COVID-19 | Phase 3 | 2021-12-15 |
| Completed | Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) Covid19 | Phase 3 | 2021-08-07 |
| Completed | Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen) Covid19 | Phase 2 | 2021-05-30 |
| Completed | Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Ast Allergic Asthma, Uncontrolled Moderate to Severe | Phase 3 | 2021-01-18 |
| Completed | Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration | Phase 3 | 2019-10-01 |
| Completed | Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis Multiple Sclerosis, Relapsing-Remitting | Phase 3 | 2019-08-19 |
| Unknown | Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes Diabetes Mellitus, Type 2 | Phase 3 | 2019-06-20 |
| Completed | Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer HER2-positive Breast Cancer | Phase 3 | 2018-08-11 |
| Unknown | Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 3 | 2018-01-20 |
| Completed | Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Scle Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | 2017-12-20 |
| Completed | Pharmacokinetics and Pharmacodynamics of CinnoVex (Interferon Beta-1a) Compared to Avonex (Interferon Beta-1a) Bioequivalence, Healthy | Phase 1 | 2017-11-27 |
| Completed | A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects Bioequivalence, Phase 1 | Phase 1 | 2016-10-22 |
| Completed | Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment o Anemia in End-Stage Renal Disease | Phase 3 | 2016-06-22 |
| Completed | Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN Chemotherapy-induced Neutropenia | — | 2016-03-29 |
| Completed | Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children Idiopathic Growth Hormone Deficiency | Phase 3 | 2016-03-09 |
| Completed | Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA Active Rheumatoid Arthritis | Phase 3 | 2015-11-18 |
| Completed | Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran Relapsing Multiple Sclerosis | — | 2015-04-12 |